Načítá se...
Improving the Efficacy of Radioimmunotherapy for Non-Hodgkin’s Lymphomas
Approximately 66,000 Americans develop non-Hodgkin’s lymphomas (NHL) each year. Although the use of unlabeled antibodies such as rituximab has significantly improved survival when combined with standard chemotherapy regimens, two-thirds of lymphoma patients eventually relapse and succumb to their di...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2820155/ https://ncbi.nlm.nih.gov/pubmed/20127945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24801 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|